Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 8c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.75), $0.08 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• JPMorgan Upgrades Nanya Technology Corp (2408:TT) to Overweight
• Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight